Intellia Therapeutics Announces That Data From The Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema Will Be Presented At The European Academy Of Allergy & Clinical Immunology Annual Congress 2026

Intellia

Intellia

NTLA

0.00

Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.

Late-Breaking Oral Presentation Details:

  • Title: HAELO, a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran Ziclumeran, a CRISPR-Based Gene Editing Therapy, in Patients with Hereditary Angioedema

    Session: Immune deficiencies and autoimmunity

    Data and Time: Saturday, June 13, 2026, from 8:45 – 9:45 a.m. TRT

    Presentation Number: 100217

    Presenter: Danny Cohn, M.D., Ph.D., Internist, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam

Poster Presentation Details:

  • Title: Barriers to Normalization with Existing Treatments Among People Living with Hereditary Angioedema in Europe

    Session: Immune deficiencies and autoimmunity 02

    Data and Time: Friday, June 12, 2026, from 12:00 – 1:00 p.m. TRT

    Poster Number: D1.336

    Presenter: Henriette Farkas, M.D., Ph.D., Professor of Allergy and Clinical Immunology Director of the Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Hematology, Semmelweis University
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.